Genzyme banks on Myozyme facility to pump up sales

02/11/2009 | Wall Street Journal, The

Genzyme is optimistic that it will receive FDA approval by the end of this month for a manufacturing plant in Framingham, Mass., that would produce its Pompe disease drug Myozyme. The facility would boost production and dramatically increase sales this year, the company said. The firm is expected to change the name of drugs produced at the plant from Myozyme to Lumizyme to comply with the FDA's manufacturing rules.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care